Statin adjunctive therapy shortens the duration of TB treatment in mice

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 6, 2016, Pages 1570-1577

  Dutta, Noton K ^a   Bruiners, Natalie ^b   Pinn, Michael L ^a   Zimmerman, Matthew D ^b   Prideaux, Brendan ^b   Dartois, Véronique ^b   Gennaro, Maria L ^b   Karakousis, Petros C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; SIMVASTATIN; TUBERCULOSTATIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LUNG LESION; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; RECURRENCE RISK; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; HUMAN; MICROBIOLOGY; MONOCYTE; MULTIMODALITY CANCER THERAPY; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG THERAPY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE, INBRED BALB C; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84973332908     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw014     Document Type: Article

References (44)

1. Zumla AI, Gillespie SH, Hoelscher M et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14: 327-40.
2. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 2015; 15: 255-63.
3. Mahon RN, Hafner R. Immune cell regulatory pathways unexplored as host-directed therapeutic targets for Mycobacterium tuberculosis: an opportunity to apply precision medicine innovations to infectious diseases. Clin Infect Dis 2015; 61 Suppl 3: S200-16.
4. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40.
5. Davidson MH, Robinson JG. Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother 2006; 7: 1701-14.
6. Kwak B, Mulhaupt F, Myit S et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
7. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30.
8. Khurana V, Bejjanki HR, Caldito G et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131: 1282-8.
9. Rothwell C, Lebreton A, Young Ng C et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009; 389: 8-19.
10. Skerry C, Pinn ML, Bruiners N et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 2014; 69: 2453-7.
11. Guler R, Brombacher F. Host-directed drug therapy for tuberculosis. Nat Chem Biol 2015; 11: 748-51.
12. Parihar SP, Guler R, Khutlang R et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014; 209: 754-63.
13. Lobato LS, Rosa PS, Ferreira Jda S et al. Statins increase rifampinmycobactericidal effect. Antimicrob Agents Chemother 2014; 58: 5766-74.
14. Dutta NK, Pinn ML, Karakousis PC. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Antimicrob Agents Chemother 2014; 58: 4048-53.
15. Dutta NK, Pinn ML, Karakousis PC. Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. Antimicrob Agents Chemother 2014; 58: 5567-9.
16. Andreu N, Fletcher T, Krishnan N et al. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 2012; 67: 404-14.
17. Ferrari M, Fornasiero MC, Isetta AM. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 1990; 131:165-72.
18. Tsang AW, Oestergaard K, Myers JT et al. Altered membrane trafficking in activated bone marrow-derived macrophages. J Leukoc Biol 2000; 68:487-94.
19. Salamon H, Bruiners N, Lakehal K et al. Cutting edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. J Immunol 2014; 193: 30-4.
20. Prideaux B, Via LE, Zimmerman MD et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 2015; 21: 1223-7.
21. Grosset J, Truffot-Pernot C, Lacroix C et al. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992; 36: 548-51.
22. Dhillon J, Dickinson JM, Sole K et al. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40: 552-5.
23. Müller NL, Franquet T, Lee KS et al. Imaging of Pulmonary Infections. Philadelphia: Lippincott Williams & Wilkins, 2007.
24. Robichaud G, Garrard KP, Barry JA et al. MSiReader: an open-source interface to view and analyze high resolving power MS imaging files on Matlab platform. J Am Soc Mass Spectrom 2013; 24: 718-21.
25. Dutta NK, Karakousis PC. Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin? Front Microbiol 2015; 6: 1117.
26. van de Steeg E, Kleemann R, Jansen HT et al. Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials. J Pharmacol Exp Ther 2013; 347: 635-44.
27. Kyrklund C, Backman JT, Kivisto KT et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592-7.
28. Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
29. Pham PA, Flexner CW. HIV Drug Interaction Guide: DDI: The Companion Guide to MMHIV: Medical Management of HIV Infection. Knowledge Source Solutions, 2012.
30. Mahajan S, Dkhar HK, Chandra V et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARg and TR4 for survival. J Immunol 2012; 188: 5593-603.
31. Daniel J, Maamar H, Deb C et al. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 2011; 7: e1002093.
32. Tiwari V, Khokhar M. Mechanism of action of anti-hypercholesterolemia drugs and their resistance. Eur J Pharmacol 2014; 741: 156-70.
33. Antonopoulos AS, Margaritis M, Lee R et al. Statins as antiinflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519-30.
34. Lamichhane G. Mycobacterium tuberculosis response to stress from reactive oxygen and nitrogen species. Front Microbiol 2011; 2: 176.
35. Cheng SM, Lai JH, Yang SP et al. Modulation of human T cells signaling transduction by lovastatin. Int J Cardiol 2010; 140: 24-33.
36. Shimizu K, Aikawa M, Takayama K et al. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003; 108: 2113-20.
37. Rezaie-Majd A, Maca T, Bucek RA et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
38. Bruegel M, Teupser D, Haffner I et al. Statins reduce macrophage inflammatory protein-1a expression in human activated monocytes. Clin Exp Pharmacol Physiol 2006; 33: 1144-9.
39. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
40. Xu H, Liu P, Liang L et al. RhoA-mediated, tumor necrosis factor a-induced activation of NF-kB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 2006; 54: 3441-51.
41. Li Y, Qi Y, Huang TH et al. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-a/-g activator properties. Diabetes Obes Metab 2008; 10: 10-7.
42. Jemal M, Ouyang Z, Powell ML. Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. J Pharm Biomed Anal 2000; 23: 323-40.
43. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50-7.
44. Kyrklund C, Backman JT, NeuvonenMet al. Effectof rifampicinonpravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004; 57: 181-7.